Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6662656 | 1.00 | MAPT (0.53) | MAPTNPSR1PPARGNCOA1NCOA3 | |
| SCHEMBL70027 | 0.85 | NPSR1 (0.67) | MAPTNPSR1PPARGNCOA1NCOA3 | |
| SCHEMBL276955 | 0.85 | ALDH1A1 (0.58) | MAPTNPSR1LMNAALDH1A1KDM4E | |
| SCHEMBL1588287 | 0.83 | NPSR1 (0.51) | NPSR1PPARGNCOA1NCOA3LMNA | |
| SCHEMBL1587481 | 0.82 | NPSR1 (0.55) | MAPTNPSR1PPARGNCOA1NCOA3 | |
| SCHEMBL2638143 | 0.82 | ALDH1A1 (0.51) | MAPTLMNAALDH1A1KDM4EPOLB | |
| SCHEMBL16011515 | 0.81 | HDAC1 (0.61) | NPSR1PPARGNCOA1NCOA3LMNA | |
| SCHEMBL1587163 | 0.81 | ALDH1A1 (0.51) | MAPTLMNAALDH1A1TSHRKDM4E | |
| SCHEMBL1588044 | 0.81 | NPSR1 (0.40) | MAPTNPSR1PPARGNCOA1NCOA3 | |
| SCHEMBL28643715 | 0.80 | NPSR1 (0.56) | MAPTNPSR1PPARGNCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8053453-B2 | Pyrazolone compounds and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | BIOCHEM PHARMA INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1091952-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC (CA) | 2001-04-18 | — | — | EP | disclosed |
| US-6174883-B1 | ENZYME INHIBITORS OF PROSTAGLANDIN H2 SYNTHASE, 5-LIPOXYGENASE; INHIBITORS OF INTERLEUKIN-1 BIOSYNTHESIS; ANALGESICS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; BONE, CONNECTIVE TISSUE METABOLISM AND SKIN DISORDERS | PFIZER INC. | 2001-01-16 | — | — | US | disclosed |
| WO-2000000486-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5919809-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0393936-B1 | 3-substituted-2-oxindole derivatives as antiinflammatory agents | PFIZER (US) | 1995-02-22 | — | — | EP | disclosed |
| US-5300655-A | 2-carboxy-thiophene derivatives | PFIZER INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5290802-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1994-03-01 | — | — | US | disclosed |
| US-5047554-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0393936-A1 | 3-substituted-2-oxindole derivatives as antiinflammatory agents | PFIZER INC. (US) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | MAPT 3117/4885NPSR1 80/4885PPARG 1124/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | MAPT 2880/4885NPSR1 80/4885PPARG 1129/4885 |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | MAPT 3117/4885NPSR1 80/4885PPARG 1124/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | MAPT 3117/4885NPSR1 80/4885PPARG 1124/4885 |
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | ITGB5, ITGB2, ITGA2 | MAPT 4652/4885NPSR1 4057/4885PPARG 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.